News & updates

LUMC talent Edouard Fu receives NWO Rubicon grant to conduct research at Harvard Medical School

Created on:


October 6, 2021

Edouard Fu, PhD student at the Department of Clinical Epidemiology at the LUMC, uses big data to study the effectiveness and safety of kidney, diabetes and heart failure treatments. With a Rubicon grant from NWO, Edouard will conduct further research at Harvard Medical School over the next two years.

In the first round of Rubicon 2021, a total of 24 newly graduated scientists were selected to conduct research abroad at prestigious institutions such as Oxford and Harvard. 

Wonder drugs for diabetics?

Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a new group of medications used for treating patients with type 2 diabetes, kidney disease, or heart failure. The potential impact of this novel medication class is enormous: type 2 diabetes currently affects more than 400 million people worldwide, whereas heart failure is the leading cause of hospitalizations in the Western world. 

Considered a breakthrough in the treatment of diabetes and heart failure, Edouard Fu – however – highlights that initial clinical trials on the effectiveness and safety of SGLT2 inhibitors do not portray the whole picture quite yet. “These trials included very selective patient populations and their study size and duration is often not sufficient to investigate rare – but potentially serious safety outcomes. By applying cutting-edge statistical methods to big data of more than 200 million patients, we will be able to investigate the effectiveness and safety of these drugs in patients with diabetes and heart failure in a real-life setting.” 

Read the full article here.


More news & updates

Background Image Of A Scientist Recording Test Results In A Lab

Janssen COVID-19 vaccine approved for use in EU on March 11

March 11, 2021

The Janssen-Cilag International N.V COVID-19 vaccine has received authorization for emergency use by the European Medicines Agency (EMA) on March 11. Developed with fundamental support from the Molecular Virology group of the Leiden University Medical Centre (LUMC), it is the fourth vaccine to be administered in the European Union. The Netherlands has ordered more than 11 million vaccine doses.

Studying abroad during a pandemic

July 15, 2021

For many students from the LUMC’s academic programmes, studying abroad is an indispensable experience. Doing part of your studies abroad is a special experience, not only because of the sense of adventure of being abroad, also to develop a broader perspective on Life Sciences & Health, a highly international field. So, you can imagine the LUMC’s International Office’s struggle to have to tell students ‘no’ for a study experience abroad in the midst of the corona pandemic. In addition, the many lockdowns worldwide increased the workload dramatically for the International Office. Evelien Hack, Head of the International Office and Sandra van Deursen, senior administrative assistant, share how corona has impacted studying abroad.

Body cells under a microscope. A good illustration as a representation of research of stem cells, cellular therapy and regeneration and many other concepts. 3D illustration

LUMC and Ixaka announce collaboration to advance cell therapy development

March 30, 2021

The Leiden University Medical Center (LUMC) and Ixaka Ltd. have announced a research collaboration on 30 March 2021, to better understand REX-001, Ixaka’s lead cell therapy product. The project will be led by Professor Paul Quax, Head of Experimental Vascular Surgery at the LUMC, to support accelerated development of REX-001 in Phase III clinical trials for the treatment of chronic limb-threatening ischemia (CLTI).

Stay up to date with news, inspirations and events.

© LUMC Global. All rights reserved. Website door philogirl

Contact

Social